Innoviva, Inc. Common Stock (INVA) Stock Price

INVAStock

$20.78+20.46%52W

Market Cap$1.50B

P/E5.54x

PEG Ratio3.11

Div yield—

Beta0.38

INVA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-24.00%

Price vs S&P 500 (4W)0.09%

PEG Ratio3.11

VGM Score66.97

P/E Ratio (Annual)5.54x

P/CF (Annual)7.62x

Book Value / Share (Quarterly)$16.98

P/TBV (Annual)1.60x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)7.48%

Cash Flow / Share (Quarterly)$2.48

Price vs S&P 500 (YTD)-7.97%

Gross Margin (TTM)72.19%

Net Profit Margin (TTM)81.19%

EPS (TTM)$4.05

10-Day Avg Trading Volume0.67M

EPS Excl Extra (TTM)$4.05

Revenue Growth (5Y)4.08%

EPS (Annual)$3.20

ROI (Annual)18.96%

Gross Margin (Annual)74.80%

Net Profit Margin (5Y Avg)52.55%

Cash / Share (Quarterly)$7.97

P/E Basic Excl Extra (TTM)4.20x

Revenue Growth QoQ (YoY)19.25%

EPS Growth (5Y)10.12%

P/E Normalized (Annual)5.54x

ROA (Last FY)16.58%

Revenue Growth TTM (YoY)18.84%

EBITD / Share (TTM)$2.15

ROE (5Y Avg)31.01%

Operating Margin (TTM)36.95%

Cash Flow / Share (Annual)$2.50

P/B Ratio1.22x

P/B Ratio (Quarterly)1.36x

Net Income / Employee (Annual)$1,705,400

EV / Revenue (TTM)2.70x

Net Interest Coverage (TTM)1.30x

ROA (TTM)21.64%

EPS Growth QoQ (YoY)919.12%

EV / EBITDA (TTM)6.74x

EPS Incl Extra (Annual)$3.20

Current Ratio (Annual)14.64x

Quick Ratio (Quarterly)14.66x

3-Month Avg Trading Volume0.81M

52-Week Price Return20.46%

EV / Free Cash Flow (Annual)6.38x

P/E Incl Extra (TTM)4.20x

Revenue / Employee (TTM)$2,767,300

Tangible BV / Share (Quarterly)$13.97

P/S Ratio (Annual)3.65x

Asset Turnover (Annual)0.25x

52-Week High$25.15

Operating Margin (5Y Avg)71.09%

EPS Excl Extra (Annual)$3.20

Tangible BV CAGR (5Y)17.65%

26-Week Price Return-14.10%

Quick Ratio (Annual)13.31x

13-Week Price Return-4.28%

Total Debt / Equity (Annual)0.22x

Current Ratio (Quarterly)16.01x

Enterprise Value$1.19B

Revenue / Share Growth (5Y)10.36%

Asset Turnover (TTM)0.27x

Book Value / Share Growth (5Y)24.17%

Revenue / Employee (Annual)$2,587,000

Inventory Turnover (Annual)2.84x

Pretax Margin (Annual)79.47%

Cash / Share (Annual)$7.59

3-Month Return Std Dev22.85%

Net Income / Employee (TTM)$2,246,800

EBITDA CAGR (5Y)-11.90%

EBITDA Interim CAGR (5Y)-11.45%

ROE (Last FY)23.12%

Net Interest Coverage (Annual)0.32x

EPS Basic Excl Extra (Annual)$3.20

P/FCF (TTM)8.34x

Receivables Turnover (TTM)4.42x

EV / Free Cash Flow (TTM)6.60x

Total Debt / Equity (Quarterly)0.21x

EPS Incl Extra (TTM)$4.05

Receivables Turnover (Annual)4.58x

ROI (TTM)24.68%

P/S Ratio (TTM)3.41x

Pretax Margin (5Y Avg)70.53%

Revenue / Share (Annual)$4.85

Tangible BV / Share (Annual)$12.52

Forward P/E9.19x

Free OCF CAGR (5Y)-9.85%

Price vs S&P 500 (52W)4.93%

P/E Ratio (TTM)4.20x

EPS Growth TTM (YoY)1744.60%

Year-to-Date Return3.95%

5-Day Price Return-3.12%

EPS Normalized (Annual)$3.20

ROA (5Y Avg)15.78%

Net Profit Margin (Annual)65.92%

Month-to-Date Return-2.03%

Cash Flow / Share (TTM)$1.03

EBITD / Share (Annual)$2.10

EPS Growth (3Y)12.50%

Operating Margin (Annual)39.81%

LT Debt / Equity (Annual)0.22x

P/CF (TTM)7.84x

ROI (5Y Avg)17.85%

P/E Excl Extra (TTM)4.20x

LT Debt / Equity (Quarterly)0.21x

EPS Basic Excl Extra (TTM)$4.05

P/TBV (Quarterly)1.65x

P/B Ratio (Annual)1.27x

Inventory Turnover (TTM)2.78x

Pretax Margin (TTM)95.32%

Book Value / Share (Annual)$15.71

Price vs S&P 500 (13W)-6.97%

Net Margin Growth (5Y)-0.21%

Beta0.38x

P/FCF (Annual)8.05x

Revenue / Share (TTM)$5.99

ROE (TTM)30.03%

52-Week Low$17.10

vGradeB

gGradeB

mGradeB

vgmGradeB

INVA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.50	$0.56	+11.46%(+$0.06)
Q1 2026	May 6, 2026	$0.43	$0.47	+8.79%(+$0.04)
Q4 2025	Feb 25, 2026	$0.42	$0.47	+11.15%(+$0.05)
Q3 2025	Nov 5, 2025	$0.39	$0.38	-0.10%(-$0.00)
Q2 2025	Aug 6, 2025	$0.50	$0.77	+54.00%(+$0.27)

INVA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.09

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
INVAInnoviva, Inc. Common Stock	B	B	B	3.4x	18.8%	72.2%	10.1%	$20.78
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Innoviva, Inc. Common Stock

Innoviva Inc generates revenue through a portfolio of pharmaceutical royalties and operating assets in critical care and infectious disease. Its holdings include branded respiratory therapies such as Trelegy, Anoro, and the Relvar/Breo/Ellipta franchise, which provide recurring revenue streams from established, marketed products.